Orforglipron Hemicalcium hydrate

an orally active, non-peptide small-molecule agonist targeting the glucagon-like peptide-1 receptor (GLP-1R). It is mainly studied for type 2 diabetes management, blood glucose reduction, and body weight control. It is grouped under the following drug class(es): GLP‑1 Receptor Agonists. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Orforglipron calcium hemihydrate and Orforglipron calcium salt hydrate. Its PubChem CID is 177669117.

CAS No 3008544-96-2
Molecular Formula C96H100CaF4N20O12
Molecular Weight 1842.00 g/mol
Synonyms Calcium bis(3-[(1S,2S)-1-[5-[(4S)-2,2-dimethyloxan-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-1,2,4-oxadiazol-5-olate) hydrate.

Frequently Asked Questions